Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir + PegIFN/RBV in Vietnamese Subjects with CHC GT1
NCT01641666Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of boceprevir in hepatitis C (HCV), sponsored by Merck & Co.. Planned start May 2014; status: withdrawn.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01641666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01641666.